ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

2:00PM-3:30PM: Abstract Number: 1639

PsA Patients of Diverse Ethnic and Racial Backgrounds Experience More Skin Psoriasis, Increased Pain, and Higher Rates of Radiographic Axial Disease

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Psoriatic Arthritis

2:00PM-3:30PM: Abstract Number: 1640

Psoriatic Disease Associated with Neuroconnectivity Alterations in the Default Mode Network

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Psoriatic Arthritis

2:00PM-3:30PM: Abstract Number: 1606

Purinergic Signaling as a Potential Therapeutic Target for APS Thromboinflammation

Abstracts: Antiphospholipid Syndrome

2:00PM-3:30PM: Abstract Number: 1624

Racial Disparities Impact Achieving LLDAS and Glucocorticoid Use in Pediatric Lupus: A CARRA Registry Study

Abstracts: Pediatric Rheumatology – Clinical II: Connective Tissue Disease

2:00PM-3:30PM: Abstract Number: 1619

Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis

Abstracts: Health Services Research II

2:00PM-3:30PM: Abstract Number: 1599

Single-Cell RNA Sequencing Reveals Cellular Drivers of UV-mediated Skin Injury in Cutaneous Lupus

Abstracts: SLE – Etiology & Pathogenesis

2:00PM-3:30PM: Abstract Number: 1598

Single-cell Spatial Proteomics Identifies Intraglomerular Myeloid Cells in Membranous Lupus Nephritis

Abstracts: SLE – Etiology & Pathogenesis

2:00PM-3:30PM: Abstract Number: 1597

Staphylococcus Aureus Peptidoglycan Induces Pathogenic Autoantibody Production via Autoreactive B Cell Receptor Clonal Selection, Implications in Systemic Lupus Erythematosus

Abstracts: SLE – Etiology & Pathogenesis

2:00PM-3:30PM: Abstract Number: 1613

Tetrodotoxin Sensitive Nav1.7 Sodium Channel SCN9A Gene Polymorphism rs6754031(T >G) Is Associated with Fibromyalgia

Abstracts: Fibromyalgia & Other Clinical Pain Syndromes

2:00PM-3:30PM: Abstract Number: 1644

The EISER Study: Identifying Microbial Factors Associated with Subclinical Gut Inflammation in Spondyloarthritis Patients

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Psoriatic Arthritis

2:00PM-3:30PM: Abstract Number: 1628

The Impact of Cardiovascular and Cerebrovascular Disease on the Risk of Dementia in Rheumatoid Arthritis. a Mediation Analysis

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Comorbidities

2:00PM-3:30PM: Abstract Number: 1646

The Real-World Experience of Combined Cranial and Large Vessel FDG-PET/CT in the Investigation of Giant Cell Arteritis

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Imaging

2:00PM-3:30PM: Abstract Number: 1641

The Window of Opportunity in Psoriatic Arthritis: Similar to Rheumatoid Arthritis?

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Psoriatic Arthritis

2:00PM-3:30PM: Abstract Number: 1615

Therapeutic Hydroxychloroquine Blood Levels Are Cost Effective and May Reduce Health Disparities by Reducing Lupus Hospitalizations

Abstracts: Health Services Research II

2:00PM-3:30PM: Abstract Number: 1614

Therapy Combining Millimeter Wave-based Neuromodulation with Coaching for the Improvement in Quality of Life of Patients with Fibromyalgia: A Prospective, Multicenter, Randomized, Controlled Trial

Abstracts: Fibromyalgia & Other Clinical Pain Syndromes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].